Dr. Reddy's Laboratories has expanded its partnership with Sanofi Healthcare to introduce Beyfortus, a novel drug preventing ...

Dr Reddy’s and Sanofi partner to launch Beyfortus, a novel drug to prevent respiratory syncytial virus in infants.

AstraZeneca reports mixed first-quarter 2025 results. The fall in pre-market is likely due to the soft sales performance of ...

Dr Reddy’s & Sanofi Healthcare expand partnership to unveil Beyfortus, a novel drug to prevent RSV in India: Our Bureau, Bengaluru Tuesday, April 29, 2025, 12:15 Hrs [IST] Dr Re ...

Under the agreement, Dr Reddy's will have exclusive rights from SHIPL to promote and distribute Beyfortus within the country ...

Beyfortus, which has been approved for use in the European Union, US, China, Japan, among several countries globally, received its marketing authorisation approval from India’s Central Drugs ...

Sanofi (ENXTPA:SAN) saw a 2.85% increase in its share price last week, coinciding with notable company updates. The pharmaceutical giant announced a dividend increase to €3.92 per share during its ...

This was driven by launches, Dupixent, and favorable Beyfortus phasing. Sales increased 10.8% year over year and 9.7% on constant currency. U.S. sales were 4.66 billion and increased by 15.4%. The ...

The strategic portfolio includes Sobi's medicines Altuvoct, Aspaveli/Empaveli, Doptelet, Gamifant, Vonjo and Zynlonta, and royalty on Sanofi's sales of Altuviiio and Beyfortus. The presentation ...

Investing.com -- Swedish Orphan Biovitrum shares climbed 3% as the company reported a first-quarter revenue of SEK 6.45 billion marking a 3% increase YoY and surpassing consensus expectations by the ...

--U.S. FDA Delays: Sanofi is potentially exposed to any delays in reviews due to recently announced staff firings at the U.S. Food and Drug Administration. Its anti-inflammatory drug Dupixent was ...

Under the arrangement, Dr Reddy's will have exclusive rights from Sanofi to promote and distribute Beyfortus in India.